The increasing technological advances in biomarker and target discovery, pre-clinical models, personalized medicine, and clinical trial design have the potential to expedite the translation of new discoveries to clinical practice. Oncology is the area that has perhaps benefited the most from these new technologies. The Translational Cancer Medicine meeting will identify the key opportunities to improve cancer diagnosis and treatment, as well as provide case studies of successful (and not so successful) drug development. The pre-conference workshop will provide a comprehensive survey of novel cancer biomarkers. Translational Cancer Medicine is co-located with the Biomarker Assay Development meeting.